Treatment with Bacillus Calmette-Guérin (BCG) is the gold standard adjuvant immunotherapy of nonmuscle invasive bladder cancer (NMIBC), although it fails in one third of the patients. NMIBC expresses two tumorassociated O-linked carbohydrates: the disaccharide (Galβ1,3GalNAc) Thomsen-Friedenreich (T) antigen, and its sialylated counterpart (Siaα2,3Galβ1,3GalNAc) sialyl-T (sT), synthesized by sialyltransferase ST3GAL1, whose roles in BCG response are unknown. | Oxidative damage and response to Bacillus Calmette-Guérin in bladder cancer cells expressing sialyltransferase ST3GAL1